CYTH News and Press, Cyclo Therapeutics Inc. From 11/15/21

Cyclo Therapeutics (NASDAQ:CYTH): Q3 GAAP EPS of -$0.60 beats by $0.07. Revenue of $0.4M (+81.8% Y/Y) beats by $0.02M. Press Release For further details see: Cyclo Therapeutics EPS beats by $0.07, beats on revenue

Continued progress in lead development program evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “...

Live moderated video webcast discussion with N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer on Tuesday, November 16 th at 11:00 AM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the ȁ...

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 -...

– Dr. Lemere is a renowned translational researcher focused on understanding, preventing, and treating Alzheimer’s disease – Company continues to advance evaluation of Trappsol ® Cyclo™ toward Phase 2 study in Alzheimer’s disease wit...

Cortexyme's Alzheimer's drug candidate atuzaginstat appears to help those in the early stages of the disease who have an active P. gingivalis infection. Some antibiotics that act as direct antioxidants may slow down cognitive decline in anyone with Alzheimer's disease at any stage. ...

Company engaged in ongoing initiatives to help raise awareness and provide information on research and support for patients and families Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines throug...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President of Medical Affairs to participate in a Moderated round-table discussion with academics and industrial experts on October 11, 2021 at 4:30 PM (CET) / 10:30 AM (EST) Cyclo Therapeutics, Inc. (Nasdaq: C...

- Dr. Kjems is a leading global physician scientist with a proven pharma track record of drug development across multiple therapeutic areas, including chronic indications, oncology and rare diseases - - Gerald F. Cox, MD, PhD will continue offering clinical development leaders...